Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy [ChIP-seq]

ABSTRACT: Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy [ChIP-seq]

PROVIDER: PRJNA664185 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12662027_1.fastq.gz	Fastqsanger.gz
	SRR12662027_2.fastq.gz	Fastqsanger.gz
	SRR12662028_1.fastq.gz	Fastqsanger.gz
	SRR12662028_2.fastq.gz	Fastqsanger.gz
	SRR12662029.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 152

Similar Datasets

Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy

Project description:Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy

| PRJNA664131 | ENA

Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy [RNA-seq]

Project description:Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy [RNA-seq]

| PRJNA664186 | ENA

Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy [ATAC-seq]

Project description:Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy [ATAC-seq]

| PRJNA664184 | ENA

Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy [RNA-seq]

Project description:Rna-seq analysis of wild type and Kmt2c mutant hematopoietic progenitors

2021-02-18 | GSE158160 | GEO

Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy [ChIP-seq]

Project description:ChIP-seq analysis of wild type and Kmt2c mutant hematopoietic progenitors

2021-02-18 | GSE158159 | GEO

Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy [ATAC-seq]

Project description:ATAC-seq analysis of wild type and Kmt2c mutant hematopoietic progenitors

2021-02-18 | GSE158158 | GEO

Kmt2c-mutations superimpose properties of activated and quiescent HSCs to convey a selective advantage after chemotherapy

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-02-18 | GSE158162 | GEO

Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.

Project description:The myeloid tumor suppressor KMT2C is recurrently deleted in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), particularly therapy-related MDS/AML (t-MDS/t-AML), as part of larger chromosome 7 deletions. Here, we show that KMT2C deletions convey a selective advantage to hematopoietic stem cells (HSCs) after chemotherapy treatment that may precipitate t-MDS/t-AML. Kmt2c deletions markedly enhance murine HSC self-renewal capacity without altering proliferation rates. Haploid Kmt2c deletions convey a selective advantage only when HSCs are driven into cycle by a strong proliferative stimulus, such as chemotherapy. Cycling Kmt2c-deficient HSCs fail to differentiate appropriately, particularly in response to interleukin-1. Kmt2c deletions mitigate histone methylation/acetylation changes that accrue as HSCs cycle after chemotherapy, and they impair enhancer recruitment during HSC differentiation. These findings help explain why Kmt2c deletions are more common in t-MDS/t-AML than in de novo AML or clonal hematopoiesis: they selectively protect cycling HSCs from differentiation without inducing HSC proliferation themselves.

| S-EPMC7951951 | biostudies-literature

Mass spectrometry of histone post-translational modifications in WT and KMT2C/2D dKO urothelial cells

Project description:KMT2C and KMT2D are two of the frequently mutated epigenetic modifiers in urothelial cancer. To compare the histone post-translational modification with Kmt2c/d loss, we performed mass spectrometry analysis of histones from Kmt2c/d WT and dKO urothelial cells.

2025-01-08 | PXD056439 | Pride

Connect-seq to superimpose molecular on anatomical neural circuit maps

Project description:We report RNA sequencing of single virus-infected neurons upstream of neurons producing corticotropin-releasing hormone (CRH). Analyses of PRV-infected transcriptomes reveal neurons upstream of CRH neurons express diverse and a large variety of signaling molecules. The molecular identities of upstream neurons can be used to superimpose a molecular on neuroanatomical circuit maps.

2019-11-06 | GSE139923 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data